Interleukin 6 as a Treatment Target for Depression
Éimear M. Foley(University of Bristol), Golam M. Khandaker(Avon and Wiltshire Mental Health Partnership NHS Trust), Peter B. Jones(University of Cambridge), Nicholas Turner(University of Bristol), Glyn Lewis(University College London), Muzaffer Kaşer(Cambridgeshire and Peterborough NHS Foundation Trust), Hannah J. Jones(University Hospitals Bristol NHS Foundation Trust), Ruta Margelyte(University of Bristol)
Cited by 0
Related Papers
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome
|Neurology|2021|322
Peripheral blood cellular immunophenotype in depression: a systematic review and meta-analysis
|Molecular Psychiatry|2022|122
Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
|Therapeutic Advances in Musculoskeletal Disease|2020|48
A novel biomarker of interleukin 6 activity and clinical and cognitive outcomes in depression
|Psychoneuroendocrinology|2024|32
Clinical phenotypes of depressed patients with evidence of inflammation and somatic symptoms
|Comprehensive Psychoneuroendocrinology|2021|31